downgrad neutral lower tp
downgrad neutral long-tim bull
downgrad share neutral follow underwhelm guidanc
addit question strength busi
perform net incom per share pnip guidanc inde
compani previous guid meaning benefit
lower tax rate lower share count actual revenu guidanc
lighter expect
addit question rais valu pipelin base busi
compani commentari also leav us cautiou pipelin depress
drug rapastinel view key catalyst regener
interest stock impair charg gener
medicin busi unit count alloc anti-
infect rais question us visibl
strength allergan underli busi financi like still
valu certain pipelin asset point seen mani
disappoint along way give much credit asset
may continu perform well see enough valu visibl
beyond franchis continu recommend allergan share
lower target price lower target price
base blend dcf rel valuat use
wacc given ad question busi
along perpetu growth dcf appli
ev/ebitda multipl deriv rel valuat
pnip main risk
view allergan better worse-than-expect clinic data
especi pipelin drug cgrp rapastinel surpris
perform core market product especi aesthet and/or
chang compani team strategi could influenc
valu stock
valuat metric
number share
price month
outperform neutral
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
allergan global brand pharmaceut compani develop
commerci product focus four key therapeut
area eye care aesthet gastrointestin
price jan rate outperform neutral target price analyst vamil
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
blue sky valuat base greater sale botox
vraylar linzess oral cgrp compar current base
case assumpt also model higher gross margin
oper margin base case assumpt blue sky
valuat base dcf driven wacc
grey sky valuat base lower sale botox
vraylar linzess oral cgrp compar current base
case assumpt also model lower gross margin
oper margin base case assumpt grey sky
valuat base dcf driven wacc
 close
disappoint pipelin progress date
new question us rapastinel
variou controversi allergan past coupl year comfort
recommend name anchor believ upsid potenti
pipelin howev time seen number disappoint
develop pipelin without mani product deliv unexpect upsid
look back allergan manag project pipelin last day
novemb paint fairli grim pictur mani product either
delay disappoint abandon complet figur
product list point believ vraylar one
exceed allergan team preliminari peak sale estim provid back
estim vraylar sale oral cgrp reason
opportun end rang provid back figur
figur allergan pipelin project day larg
figur credit suiss sale project
exclus right paratek
head view pipelin depress drug rapastinel import
catalyst pipelin product current manag team directli
involv acquir one pick bigger acquisit
potenti address area unmet need therapeut area allergan
team signific expertis launch previous shift
data mention back remain optimist overal outlook
data phase rapastinel trial acut treatment adjunct major
depress disord expect optimist data
product would highlight new potenti growth driver compani improv
sentiment stock base list acut trial rapastinel
clinicaltri gov appear two three trial complet novemb
third still on-going figur given surpris allergan limit
commentari call product figur especi previous
consid one six star pipelin
beyond rapastinel number pipelin updat expect
figur believ hold potenti posit impact
allergan stori abicipar see data mapl trial
inflamm rate optim formul like lower
seen formul use origin phase trial expect rate still
higher physician experi current avail therapi believ
upsid abicipar revenu like come product approv
compani abl show commerci effect street
current expect ubrogep allergan oral cgrp acut treatment migrain
file regul year believ upsid like come
compani abl show product bigger commerci
success current believ vraylar one clear success stori
pipelin expect posit regulatori decis fda may expand
use product bipolar depress although believ event alreadi
expect investor
number
random double-blind placebo-control multicent studi rapastinel adjunct
therapi major depress disord
random double-blind placebo-control multicent studi rapastinel adjunct
therapi major depress disord
random double-blind placebo-control multicent studi rapastinel adjunct
therapi major depress disord
random double-blind placebo-control multicent studi rapastinel adjunct
therapi prevent relaps patient major depress disord rap-md-
open-label long-term safeti studi rapastinel adjunct therapi patient
random double-blind placebo-control multicent studi rapastinel
monotherapi patient major depress disord
random double-blind placebo-control multicent studi rapastinel
monotherapi patient major depress disord
random double-blind placebo-control multi-cent studi rapastinel
prevent relaps patient major depress disord
open-label long-term extend access protocol rapastinel adjunct
monotherapi treatment patient major depress disord
www clinicaltri gov access jan
enrol
figur manag commentari rapastinel confer call
rapastinel im tri get perspect know
data come acut studi im
tri get sens import data think
outlook product weve highlight potenti
clearli import develop five program forrapastinel studi on-going forrapastinel
conclud get data import mileston us id put context categori
tremend need novel rapid-onset antidepress allergan patient could
import advanc interest see result later year
guy talk littl bit aboutrapastineland plan
reveal data data hous yet
what plan reveal data expect
multipl press releas trial plan realli bring
data reveal multipl trial simultan
like see later year
realiz there question onrapastinel want
clarifi guy phase report intern yet
expect volatil variabl depress trial
weve seen program
also phase program equal excit like tri pick favorit child
import us im sure would read anyth press releas tri diminish import
one late-stag program
three acut mainten open label trial complet enrol that clinicaltri gov
absolut schedul plan top line result studi come close enough
go top line result three time whatev reason end spread far apart top
line separ
essenti polici within allergan close time bundl substanti
differ time multipl studi readout individu quit convent
industri way
regard rapastinel mention answer previou question yeah expect abl top line result
thank question variabl depress studi look certainli monoamin modul
effect antidepress abil distinguish agent placebo clinic trial well-known issu smaller
proport well-control clinic studi actual demonstr signific differ activ drug placebo
clearli move new mechan action still anticip larg placebo effect trial whether go
difficult distinguish activ agent like rapastinel mechan action monoamin modul
placebo time tell roll data
figur pipelin updat main upcom catalyst could regener interest agn share
ubrogep acut treatment migrain
atogep prevent migrain
rapastinel adjunct treatment depress
atogep prevent migrain
expect fda file nda
phase initi chronic migrain
top-line result three phase acut studi major depress disord
regulatori submiss fda
initi phase studi us/eu
phase initi dme
regulatori submiss fda
initi phase studi asia/canada
phase result episod migrain
visibl underli financi also
even defend allergan stock past sever quarter
struggl time understand compani financi report faith
strength allergan core cash-pay aesthet busi well saw
potenti upsid pipelin kept us comfort recommend stock
time period new question lack clariti
earn releas confer call remov remain comfort
main question revolv around pre-tax impair charg
compani took quarter includ intang asset impair
write off relat goodwil figur compani disclos
intang asset impair charg relat kybella clearli live
expect product acquir kythera
cash also wrote goodwil relat anti-infect
busi prepar sell busi addit goodwil write
off gener medicin report appear due combin
factor driven enterpris valu busi fair valu
leav us wonder allergan underli busi actual worth
figur allergan taken number larg impair recent quarter
us million
impair kybella intang asset
impair truetear intang asset
impair goodwil
impair anti-infect held sale
impair restasi intang asset
impair aczon intang asset
decreas realiz
warner chilcott
impair
psoriasi
vita pharma
impair
ipr
impair
asset held sale
mani reader like know regularli assess diverg
non- result compani comment
allergan clear outlier coverag term degre variat
charl martineau univers toronto figur larg cap pharma gap non-gaap gaap net incom sale
spread million spread sale
sale
figur agn gap non-gaap gaap net incom sale
spread million spread sale
sale
perhap concern us fact sec even comment
uncommon magnitud adjust allergan make
non-gaap result industri variat sec advis
allergan longer refer bottom line result adjust earn per share
instead use perform net incom per share label use specif
sec advis allergan retitl adjust earn per share metric
clearli reflect extent departur concept earn addit
sec mention titl consist fact typic exclud
half oper expens clearli state non-gaap result
never burden cost acquir underli product
current gener revenu
holt len also give allergan score poor
overal account qualiti
credit suiss holt account qualiti score base patent quantit
methodolog identifi account anomali across uniqu categori hundr
financi statement line item poor score indic compani rank bottom
quintil region-rel basi start point identifi potenti risk
warrant qualit investig allergan account qualiti score holt len
poor driven poor averag rate number metric figur
addit inform holt account qualiti score holt team
assess allergan pleas consult holt account tax expert ron graziano
figur holt assess allergan account qualiti
price
new price target price figur base
blend discount cash flow dcf figur rel valuat
figur
dcf forecast cash flow use termin
growth forecast thereaft along wacc wacc higher
use previous see greater risk overal stori model cash
flow follow week updat
rel valuat util ev/ebitda multipl base
ebitda estim prefer ev/ebitda multipl allergan price-to-earnings multipl
use previous use larger cap compani better
account allergan debt balanc valuat
blue sky valuat allergan base greater sale key
market pipelin product botox vraylar linzess oral cgrp
well slightli higher oper margin profil compani
grey sky valuat allergan base lower sale key market
pipelin product botox vraylar linzess oral cgrp well
slightli lower oper margin profil compani
figur per share target price base blend
dcf rel valuat
figur dcf sensit analysi show impact
differ wacc perpetu growth assumpt
note peer averag multipl base follow peer teva
compani data credit suiss pharmavalu databas holt bloomberg profession servic thomson reuter credit suiss estim
npv ev lc/share
revenu segment
revenu product
sale
net interest incom
us million unless otherwis state
acquisit divestitur integr licens charg
accret fair-valu adjust conting consider
incom tax item incom tax adjust
acquisit divestitur integr licens charg
accret fair-valu adjust conting consider
incom tax item incom tax adjust
us million unless otherwis state
sale
research develop
sell gener administr
incom incom tax non-controlling
net incom continu oper
provis incom tax
incom discontinu oper net tax
incom loss attribut non-controlling interest
net incom attribut sharehold
weight average share calcul dilut ep
 includ mileston sale
author report wish acknowledg contribut made selvakumar
nallasami paul singh employe crisil global research analyt
busi divis crisil limit crisil limit third-parti provid off-shore
research servic credit suiss
compani mention price
